Skip to main navigationSkip to main content
The University of Southampton
Southampton Clinical Trials Unit

ProCAID (Phase II)


An open label phase I/randomised, double blind phase II study in metastatic castration resistant Prostate Cancer of AZD5363 In combination with Docetaxel and prednisolone chemotherapy  


A phase I/II trial to determine if the addition of the AKT inhibitor AZD5363 to docetaxel and prednisolone (DP) prolongs progression free survival (PFS) in metastatic castration resistant prostate cancer (mCRPC) to a degree worthy of further investigation.


Primary Endpoints:

  • Phase I
    • Determination of a suitable dose of AZD5363 using a 4 days on/3 days off continuous schedule, in combination with DP
  • Phase II
    • Progression free survival (PFS) in patients receiving AZD5363 versus placebo when combined with DP in mCRPC

Secondary Endpoints:

  • Phase I 
    • Safety and tolerability profiles using CTCAE version 4.03
    • AZD5363 pharmacokinetics in combination with DP
  •  Phase II
    • Overall survival
    • Bone pain changes using the brief pain inventory
    • PFS excluding biochemical (PSA) alone progression
    • Biochemical (PSA) response rates according to PCWG2 criteria
    • Safety and tolerability profiles using CTCAE version 4.03

Trial Design

ProCAID will first comprise a dose-finding, single arm, open label phase I study exploring the combination of AZD5363 and Docetaxel and prednisolone chemotherapy (DP). This will be followed by a double-blind, randomised phase II study comparing DP + AZD5363 with DP + placebo. All patients will have chemotherapy naive mCRPC and will be suitable for treatment with palliative docetaxel. Patients may, but are not required to, have had prior second generation anti-hormonal therapies (e.g., abiraterone, enzalutamide).

  • Phase I
    • AZD5363 at dose levels between 320 mg bd and 480 mg bd, taken 4 days on/3 days off, continuously starting from day 2 of cycle 1 of DP onwards.
  • Phase II
    • AZD5363 twice daily at a dose level  defined in phase I (experimental arm) or matching placebo (control arm), taken 4 days on/3 days off, continuously from day 2 of cycle 1 of DP onwards.

Trial Status

Closed to recruitment - In Follow up


Metastatic castration resistant prostate cancer (mCRPC) patients suitable to receive palliative docetaxel chemotherapy

Phase I: 3-18 patients

Phase II: 132 (66 per arm)



Trial Team:

Senior Trial Manager:

Ellice Marwood (023 8120 5608)

Trial Manager:

Nicky Downs (023 8120 5302)

Clinical Data Coordinator:

Mary Ellis (023 8120 5698)

Contact information


Fax: 0844 7740 621

SAE Reporting: or 0844 7740 621


Essential Trial Documents

ProCAID - Protocol v12 20-Mar-2019

ProCAID - AZD5363 IB Edition 10

ProCAID - Patient Information Sheet Phase II v8 21-Jun-2018

ProCAID - Informed Consent Form Phase II v8 21-Jun-2018

ProCAID - GP Letter Phase II v6 21-Jun-2018

ProCAID - Phase II - Patient Diary 21 Day Cycle v3 20-Mar-2019

ProCAID - Phase II - Patient Diary Additional Week v3 20-Mar-2019

ProCAID - Phase II - Patient Diary 21 Day Cycle GUIDANCE

ProCAID - Phase II - Patient Cards v2 22-Aug-2017

ProCAID - Brief Pain Inventory v2 02-Feb-2018

ProCAID - Phase II - Brief Pain Inventory Diagram Scoring System v1 08-Ot-2015

Pharmacy Documents

ProCAID - Phase II - Pharmacy Manual v1 17-Jul-2015

ProCAID - Pharmacy File Index v2 17-Sep-2015

ProCAID - Phase II - Drug Accountability Log v1 27-Jan-2015

ProCAID - Phase II - Drug Destruction Log v1 27-Jan-2015

Investigator Site File

ProCAID - Study Contacts and Information Page v4 02-Oct-2015

ProCAID - ISF Index v4 09-Oct-2015

ProCAID - Master Patient List v2 27-Aug-2014

ProCAID - Screening Log v3.0 02-Nov-2015

ProCAID - Labels for Patient Records L7173 v2 27-Aug-2014

ProCAID - Site Visit Log v2 27-Aug-2014

ProCAID - Delegation Log V3 22-Mar-2016

SAE Documents

ProCAID - Phase II - SAE/SUSAR Report Form v4 15-Sep-2016

ProCAID - Instructions for completion of Serious Adverse Event Reporting v2 04-May-2017

ProCAID - Phase II - SAE/SUSAR Follow-Up Form v1.0 08-Oct-2015

ProCAID - Phase II - Section E Continuation SAE/SUSAR Report Form v1 08-Oct-2015

IWRS (Cenduit)

ProCAID - IWRS Training Certificate v3 20-Dec-2016

ProCAID - Site, Investigator and Pharmacist User Guide v4


ProCAID - Phase II - eCRF Completion Guidance v3 15-Nov-2018

Translational Sample Documents

ProCAID - Phase II - Sample Collection Guidance v1 14-Oct-2015

ProCAID - Sample Storage and Shipment Log v2 27-Aug-2014

ProCAID - Central Laboratory Contact Information v1 10-Feb-2014

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.